Synedgen, a biotechnology company using glycopolymer chemistry to develop drugs that enhance and control signaling in the innate immune system, today announced supplemental funding from the National Eye Institute (NEI) of the NIH to identify a lead molecule from the company’s ocular mustard gas injury program to move into animal studies.


Research reported was supported by the National Eye Institute (NEI/NIH) and the NIH Office of the Director (OD) under Award Number U01EY030406. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Synedgen Receives Supplemental NEI Funding to Identify Lead Development Candidate for Ocular Mustard Gas Injury Program

Description

Company Information

Synedgen Receives Supplemental NEI Funding to Identify Lead Development Candidate for Ocular Mustard Gas Injury Program

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Company Information